U.S. SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, D.C.

                                   FORM 12b-25


          NOTIFICATION OF LATE FILING                   SEC File Number 0-18105

                                                       
[ ] Form 10-K and Form 10-KSB [ ] Form 20-F [x] Form 10-Q and Form 10-QSB
[ ] Form N-SAR

     For Period  Ended:  November 30, 1998
     Transition  Report on Form 10-K [ ]
     Transition Report on Form 20-F [ ] 
     Transition Report on Form 11-K [ ] 
     Transition Report  on Form 10-Q [ ]  
     Transition  Report  on Form  N-SAR 
     for the Transition Period Ended:_________________
=============================================================================
Nothing  in this  form  shall be  construed  to imply  that the  Commission 
has verified any information contained herein.
============================================================================= 
If the notification relates to a portion of the filing checked above,  
identify the Item(s) to which the notification relates:

=============================================================================
Part I - Registrant Information
=============================================================================
Full Name of Registrant:   VASOMEDICAL, INC.
Former Name if applicable: N/A  
Address of Principal Executive Office:
              180 Linden Avenue
              Westbury, New York   11590
=============================================================================
Part II - Rules 12b-25(b) and (c)
=============================================================================
     If the subject report could not be filed without  unreasonable effort or 
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the 
following should be completed. Check appropriate box.

[ ] (a) The reasons  described  in  reasonable  detail in Part III of this form
could not be eliminated without unreasonable effort or expense;



[x] (b) The subject annual report,  semi-annual  report,  transition  report on
Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the  fifteenth  calendar day following  the  prescribed  due date; or the
subject  quarterly report or transition  report on Form 10-Q, or portion thereof
will be filed on or before the fifth  calendar day following the  prescribed due
date; and

[ ](c) The accountant's statement or other exhibit required by Rule 12b- 25(c)
has been attached if applicable.
==============================================================================
Part III - Narrative
==============================================================================
State below in  reasonable  detail the  reasons  why Form 10-K and Form  10-KSB,
20-F,  11-K, 10-Q and Form 10-QSB,  N-SAR,  or the transition  report or portion
thereof could not be filed within the prescribed period.   The financial 
statements and related material are not presently available.

==============================================================================
Part IV - Other Information
==============================================================================
     (1)  Name and telephone number of person to contact in regard to this
notification:
              Joseph Giacalone   (516) 997-4600 ext. 121

     (2) Have all other periodic  reports  required under section 13 or 15(d) of
the Securities  Exchange Act of 1934 or section 30 of the Investment Company Act
of 1940  during the  preceding  12 months or for such  shorter  period  that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s).  N/A

              [x] Yes    [ ] No

     (3) Is it anticipated that any significant  change in results of operations
from the corresponding  period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

              [ ] Yes    [ ] No     Presently unknown

     If so, attach an explanation of the anticipated  change,  both  narratively
and  quantitatively,  and, if  appropriate,  state the reasons why a  reasonable
estimate of the results cannot be made.

     Vasomedical, Inc. has caused this notification to be signed on its
behalf by the undersigned thereunto duly authorized.

Date:  January 14, 1999
                                      By: /s/ Joseph A. Giacalone
                                          Secretary and Treasurer
                                          (Chief Financial Officer)   

==============================================================================

                              ATTENTION

     Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (See 18 U.S.C. 1001).